SCHEMBL22978632

SCHEMBL22978632

O=C(O)N1CCC(c2cccc3c2CCNC3)C1

nearest known ligand 0.43

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 6/20 0.42
HTR2C P28335 5/20 0.41
CD44 P16070 1/20 0.40
HTR2B P41595 3/20 0.39
HTR2A P28223 2/20 0.37
ALDH1A1 P00352 1/20 0.37
POLB P06746 1/20 0.37
BACE1 P56817 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
HTR6 P50406 2/20 0.35
DRD2 P14416 1/20 0.35
HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25427744 0.83 DDB1 (0.48) RBP4NPC1MAPTRAB9A
SCHEMBL23980883 0.78 DDB1 (0.47) RBP4NPC1MAPTRAB9A
SCHEMBL14862849 0.78 SMN1; SMN2 (0.52) NPC1RAB9ASMN1; SMN2
SCHEMBL21340182 0.77 CD44 (0.56) HTR2CCD44HTR2BHTR2AHTR6
Hydrochloric Acid SCHEMBL21326076 0.75 CD44 (0.54) HTR2CCD44HTR2BHTR6
Hydrochloric Acid SCHEMBL29588004 0.75 CD44 (0.54) HTR2CCD44HTR2BHTR6
SCHEMBL25426004 0.74 DDB1 (0.48) RBP4NPC1MAPTRAB9A
SCHEMBL14863721 0.73 TAAR1 (0.45) HTR2CCD44HTR2BHTR2A
SCHEMBL20140665 0.70 PROKR1 (0.50) RBP4ALDH1A1POLBNPC1MAPT
SCHEMBL27840577 0.69 CD44 (0.44) HTR2CCD44HTR2BHTR2AHTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023131122-A1 FUSED RING-SUBSTITUTED SIX-MEMBERED HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF 劲方医药科技(上海)有限公司 2023-07-13 WO disclosed
WO-2021026672-A1 HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS NOVARTIS AG (CH) 2021-02-18 WO disclosed